

1 **Molecular Feature-Based Classification of Retroperitoneal Liposarcoma:**
2 **A Prospective Cohort Study**

3
4 Mengmeng Xiao^{1,3†}, Xiangji Li^{2,3†}, Fanqin Bu^{2†}, Shixiang Ma³, Xiaohan Yang², Jun Chen³, Yu
5 Zhao², Ferdinando Cananzi⁴, Chenghua Luo^{1,3*}, Li Min^{2*}

6
7 ¹*Department of General Surgery, Peking University People's Hospital, 100044 Beijing, P. R.*
8 *China*

9 ²*Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University,*
10 *State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive*
11 *Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of*
12 *Digestive Disease, 100050 Beijing, P. R. China*

13 ³*Department of Retroperitoneal Tumor Surgery, Peking University International Hospital,*
14 *102206 Beijing, P. R. China*

15 ⁴*Department of Biomedical Sciences, Humanitas University, 20089, Milan, Italy*

16 [†]*These authors contributed equally to this work*

17 ***Running title: Molecular feature-based classification of RPLS***

18 **Corresponding author:**

19 Prof. Li Min, PhD, Email: minli@ccmu.edu.cn

20 Prof. Chenghua Luo, MD, PhD, Email: pkuihlch@163.com

21

22

23 **ABSTRACT**

24 **Background:** Retroperitoneal liposarcoma (RPLS) is a critical malignant disease with various
25 clinical outcomes. However, the molecular heterogeneity of RPLS was poorly elucidated, and
26 few biomarkers were proposed to monitor its progression.

27 **Methods:** RNA sequencing was performed on a training cohort of 88 RPLS patients to identify
28 dysregulated genes and pathways using clusterprofiler. The GSVA algorithm was utilized to
29 assess signaling pathways levels in each sample, and unsupervised clustering was employed to
30 distinguish RPLS subtypes. Differentially expressed genes (DEGs) between RPLS subtypes were
31 identified to construct a simplified dichotomous clustering via nonnegative matrix factorization.
32 The feasibility of this classification was validated in a separate validation cohort (n=241) using
33 immunohistochemistry (IHC) from the Retroperitoneal SARcoma Registry (RESAR). The study
34 is registered with ClinicalTrials.gov under number NCT03838718.

35 **Results:** Cell cycle, DNA damage & repair, and Metabolism were identified as the most aberrant
36 biological processes in RPLS, enabling the division of RPLS patients into two distinct subtypes
37 with unique molecular signatures, tumor microenvironment, clinical features and outcomes
38 (overall survival, OS and disease-free survival, DFS). A simplified RPLS classification based on
39 representative biomarkers (LEP and PTTG1) demonstrated high accuracy (AUC>0.99), with
40 patients classified as LEP+ and PTTG1- showing lower aggressive pathological composition
41 ratio and fewer surgery times, along with better OS (HR=0.41, $P<0.001$) and DFS (HR=0.60,
42 $P=0.005$).

43 **Conclusions:** Our study provided an ever-largest gene expression landscape of RPLS and
44 established an IHC-based molecular classification that was clinically relevant and cost-effective
45 for guiding treatment decisions.

46 **Keywords:** LEP; PTTG1; Retroperitoneal liposarcoma (RPLS); Molecular classification


47

48 INTRODUCTION

49 Retroperitoneal liposarcoma (RPLS) is a soft tissue sarcoma (STS) originating in the
50 retroperitoneum with an insidious onset. Traditional surgical resection has been regarded as a
51 primary and curable treatment strategy of RPLS for the past fifty years (*Ecker et al., 2016*).
52 However, the anatomical complexity and biological properties of sarcoma brought great
53 difficulty to achieve microscopically margin-negative resection, leading to a high postoperative
54 recurrence rate in RPLS patients. During the past decade, scientists tried to improve the
55 postoperative survival of RPLS patients by personalized surgical resection and
56 neoadjuvant/adjuvant therapies, but the effect was not satisfactory (*Littau et al., 2020; Gronchi*
57 *et al., 2015; Gronchi et al., 2009; Gronchi et al., 2013; Pisters et al., 2009*).

58 Recently, precision medicine greatly enriched the therapeutic approaches and reformed the
59 clinical decision-making chain of tumor diagnosis and treatment, prolonging the median survival
60 of main tumor types 2-10 times (*Kam et al., 2021; Zeng et al., 2022; Alifrangis et al., 2019;*
61 *Frese et al., 2021*). Biomarker-based patient stratification and targeted therapy together make up
62 the kernel of precision medicine, which is intrinsically based on the molecular profiling of
63 cancers. However, our knowledge of the molecular features of RPLS is limited, and few
64 clinically applicable molecular biomarkers and targeted drugs are available for RPLS treatment.
65 Only sporadic molecules such as CDK4 (*Pilotti et al., 2000*), MDM2 (*Binh et al., 2005*),
66 AURK4 (*Yen et al., 2019*) and CCNDBP1 (*Yang et al., 2021*) have been reported as prognostic
67 and diagnostic biomarkers, but these biomarkers were poorly represented and verified. Therefore,
68 it is crucial to reveal the molecular landscape of RPLS and explore a feasible classification for its
69 diagnosis and treatment.

70 Here, we conducted a comprehensive investigation into the molecular characteristics of
71 RPLS through the delineation of the largest gene expression landscape ever assembled for this
72 rare disease entity. By identifying both RPLS-specific genes and prognostic biomarkers, we
73 unveiled their intricate relationships with clinical parameters. Our findings revealed the existence
74 of two distinct molecular subtypes within all RPLS patients, characterized by diverse
75 pathological compositions, enriched signaling pathways, and varying clinical outcomes. This
76 highlights the limitations of relying solely on traditional pathological classification for surgical
77 decision-making in certain cases where patients exhibit favorable histological features but poor
78 prognoses. Emphasizing the pivotal role of molecular subtyping in guiding individualized
79 treatment strategies and enhancing patient management. To facilitate practical application in
80 clinical settings, we developed a simplified RPLS classification system based on key biomarkers
81 (LEP and PTTG1) representative of each subtype. Notably, this classification scheme was
82 validated in a larger cohort of RPLS patients through immunohistochemistry assays (Figure 1),
83 laying the groundwork for precise surgical interventions guided by molecular insights in the
84 realm of RPLS treatment.



85

86 *Figure 1. Flow diagram of exploring RPLS dichotomous classification*

87

88 MATERIALS AND METHODS

89 *Patients and tissue specimens*

90 Patients who diagnosed with RPLS amenable to surgical resection were eligible for the
 91 study. The RPLS histology was confirmed according to the WHO criteria done on biopsy or
 92 surgical specimen by dedicated sarcoma pathologist. The exclusion criteria included the age<18
 93 years; serious psychiatric disease that precludes informed consent or limits compliance;
 94 impossibility to ensure adequate follow-up. Tumor specimens from 88 RPLS patients (Training
 95 cohort 1, Table S1; Training cohort 2, Table S2) and another cohort of 241 RPLS patients
 96 (Validation cohort, Table S3) were obtained from our local Hospital. These cohorts are sourced
 97 from Retroperitoneal SARcoma Registry (RESAR, NCT03838718). All the patients underwent

98 curative resection from January 2015 to May 2019. RPLS tissue specimens were snap-frozen in
99 liquid nitrogen within 1 h and then stored in a -80 °C refrigerator before use. Clinical information
100 was collected from the medical records, and no patient had undergone previous chemotherapy or
101 radiotherapy. Overall survival (OS) was defined as the interval between the latest surgery and
102 death from tumors or between the latest surgery and the last observation taken for surviving
103 patients. Disease-free survival (DFS) was defined as the interval between the latest surgery and
104 diagnosis of relapse or death. Informed consent for surgical procedures and specimen collection
105 were obtained from each patient. This study has been reported in line with the REMARK criteria
106 (*McShane et al., 2005*).

107 ***RNA sequencing, primary data processing, and analysis***

108 Total RNA was extracted from Training cohort 1 (Table S4) and Training cohort 2 (Table
109 S2) using TRIzol Reagent (Invitrogen). RNA degradation and contamination were monitored
110 with 1% agarose gel. RNA purity was checked by the NanoPhotometer spectrophotometer
111 (IMPLEN, Los Angeles, CA, USA). RNA concentration was measured using the Qubit RNA
112 Assay Kit with the Qubit 2.0 Fluorometer (Life Technologies, CA, USA). RNA integrity was
113 assessed using the RNA Nano 6000 Assay Kit of the Agilent Bioanalyzer 2100 System (Agilent
114 Technologies, CA, USA).

115 A total amount of 3-5 ug RNA per sample was used as input material for the RNA library.
116 Sequencing libraries were generated using NEBNext® Multiplex Small RNA Library Prep Set
117 for Illumina® (NEB, USA) following the manufacturer's recommendations and index codes
118 were added to attribute sequences to each sample. The clustering of the index-coded samples was
119 performed on a cBot Cluster Generation System using TruSeq SR Cluster Kit v3-cBot-HS
120 (Illumina). After cluster generation, the strand-specific cDNA were sequenced on an Illumina

121 NovaSeq 6000 platform, and single-end reads were generated (Novogene Bioinformatic
122 Technology, Beijing, China).

123 FPKMs of mRNAs and non-coding RNAs in each sample were calculated by Cuffdiff
124 (v2.1.1). FPKMs were calculated based on the length of the fragments and read counts mapped
125 to this fragment. These sequencing data have been deposited at the Open Archive for
126 Miscellaneous Data (OMIX) database of China National Center for Bioinformation (CNCB)
127 under the accession number OMIX002786.

128 ***Identification of differential genes***

129 Gene difference analysis was performed to determine the differential genes (DEGs). An
130 adjusted $FDR < 0.05$ and $|\log_2 FC| > 0.585$ was considered significant. This process was conducted
131 with the R package “limma”.

132 ***Identification of prognostic genes***

133 Cox univariate regression analysis was used to screen the prognostic genes of RPLS.
134 Results of $P < 0.05$ was considered significant. This process was conducted with the R package
135 “survival”.

136 ***Gene set enrichment analysis (GSEA) and immune infiltrate analysis***

137 GSEA was performed in the tumor and normal groups to explore the biological signaling
138 pathways. Pathway annotation files were downloaded from the msigdb (www.gsea-msigdb.org)
139 platform. This process was conducted by the GSEA R package to elucidate the representative
140 HALLMARK and REACTOME pathways enriched in RPLS patients. Immunocyte infiltration
141 (immune score and stromal score) was measured by the Estimation of STromal and Immune cells
142 in Malignant Tumor tissues using Expression data (ESTIMATE) algorithm. This process was
143 completed via the “estimate” R package.

144 ***Functional annotation***

145 Functional enrichment analyses were performed to elucidate the possible biological
146 processes and signaling pathways of the prognostic genes. Gene ontology (GO) and Kyoto
147 Encyclopedia of Gene and Genomes (KEGG) analyses were conducted by R package
148 “clusterprofiler”, and the false discovery rate < 0.05 was considered significantly enriched.

149 ***Consensus clustering with t-distributed stochastic neighbor embedding (t-SNE)***

150 After evaluated the relative abundance level of related pathways, the Euclidean distance
151 was calculated between any two samples and condensed into two-dimensional points using t-
152 distributed stochastic neighbor embedding (t-SNE) (*Guo et al., 2019*) and subsequently
153 visualized automatically with the density-based spatial clustering of applications with noise
154 (DBSCAN) algorithm. This consensus clustering was conducted with the R packages “Rtsne”
155 and “dbscan”.

156 ***Consensus clustering with nonnegative matrix factorization (NMF)***

157 Nonnegative matrix factorization (NMF) was used to perform RPLS subtyping. Specifically,
158 NMF was applied to gene expression matrix A which contained gene sets of major signaling
159 pathways and prognostic genes. Matrix A was factorized into 2 nonnegative matrices W and H .
160 Repeated factorization of matrix A was performed and its outputs were aggregated to obtain
161 consensus clustering of RPLS samples. The optimal number of subtypes was selected according
162 to cophenetic, dispersion, and silhouette coefficients. This consensus clustering was conducted
163 with the R package “NMF”.

164 ***Construction of machine learning models***

165 Machine learning models based on biomarkers were constructed by logistic regression (LR),
166 support vector machine (SVM), and random forest (RF). These models were specifically tailored
167 to analyze biomarker data in order to predict clinical outcomes in surgical patients.

168 LR is a statistical method that establishes a relationship between asset of independent
169 variables and a binary outcome. It calculates the probability of an event occurring based on the
170 input features derived from biomarkers relevant to surgical patient. SVM is a supervised learning
171 algorithm that categorizes data points by identifying the optimal hyperplane that separates
172 distinct classes within a high-dimensional space. This approach effectively maps biomarker data
173 into a multidimensional space to facilitate accurate classification of patient outcomes. RF is an
174 ensemble learning technique that generated multiple decision trees during training and
175 aggregates the results to make predictions. By leveraging this method, we can enhance predictive
176 accuracy by mitigating overfitting and increasing model robustness when analyzing biomarker-
177 driven patient data.

178 The performance of these machine learning models was assessed using the area under the
179 curve (AUC) metric. A higher AUC value indicates superior discriminatory power of model in
180 distinguishing different clinical outcomes. An AUC value closer to 1.0 signifies strong predictive
181 capability, while 0.5 indicates no discriminatory ability at all. By evaluating the AUC values
182 generated by LR, SVM, and RF models, clinicians can identify which algorithm yields the most
183 reliable predictions based on biomarker profiles for surgical patients.

184 ***Immunohistochemistry***

185 The protocol was performed as previously described (*Li et al., 2022*). In brief, the LEP and
186 PTTG1 antibodies for immunohistochemistry were purchased from Proteintech (Cat No: bs-
187 0409R and bs-1881R). With deparaffinization for 15min \times 3 in dimethylbenzene and routine

188 hydration, the tissues were soaked in phosphate buffer saline (PBS) for 10min and then
189 performed high-pressure antigen retrieval (Tris-EDTA, PH=9.0) for 2.5min. After being treated
190 with a 3% endogenous catalase blocker (ZSBIO, PV-6000) for 10min, the tissues were incubated
191 in goat serum (ZSBIO, ZLI-9022) for the blocking of nonspecific reaction and then incubated
192 with primary antibody (LEP=1:300 and PTTG1=1:300) at 4°C overnight. The next day, tissues
193 were washed and incubated with goat anti-rabbit secondary antibody (ZSBIO, PV-9000) for 1h
194 at room temperature, then washed and stained with DAB reagents (ZSBIO, ZLI-9018). Then
195 hematoxylin staining, 1% hydrochloric acid alcohol differentiation, ammonia water anti-blue,
196 and neutral gum sealing.

197 The IHC results were evaluated by pathologists, the staining extent was scored as 0-100%.
198 The intensity score was defined as negative, low-expression, medium-expression, and high-
199 expression, which were documented as 0, 1, 2, and 3 respectively. The final scores were
200 calculated by the formula: $IHC\ score = Staining\ extent\ score \times Staining\ intensity\ score$.

201 ***Statistical Methods***

202 R software (version 4.1.3) was used in this study. For quantitative variables, differences
203 between the two groups and among multiple groups were analyzed by Wilcoxon's test and One-
204 way analysis of variance (ANOVA), respectively. For categoric variables, groups were compared
205 by use of Chi-square test. Survival curves were determined by Log-rank test. The
206 clinicopathological features and levels of immune infiltration were conducted by Wilcoxon's test.
207 A difference of $P < 0.05$ indicated statistical significance unless specified otherwise.

208

209 **RESULTS**

210 Baseline characteristics were shown in Table 1. Of 329 RPLS patients, 88 in training cohort and
 211 241 in validation cohort. No statistically significant differences were found in the age, sex,
 212 pathology, surgery times, tumor size, and multilocation between the two cohorts ($P>0.05$). The
 213 IHC score of LEP and PTTG1 were 1.62 (0.820) and 0.830 (0.75) in validation cohort.

214 **Table 1 Baseline characteristics of training cohort and validation cohort**

	Training cohort (N=80) [†]	Validation cohort (N=241)	P value
Age (y)	56.34 (11.14) [‡]	55.11 (10.80) [‡]	0.384
Sex			
<i>Male</i>	37 (46.25)	118 (48.96)	0.674
<i>Female</i>	43 (53.75)	123 (51.04)	
Pathology			
<i>WDLS</i>	29 (36.25)	75 (31.12)	0.078
<i>DDLS</i>	48 (60.00)	144 (59.75)	
<i>MLS and PLS</i>	3 (3.75)	5 (2.07)	
<i>NR</i>	0 (0)	17 (7.06)	
Surgery times^{††}			
<i>0-1</i>	50 (62.50)	143 (59.34)	0.834
<i>2-3</i>	21 (26.25)	73 (30.29)	
<i>4-7</i>	9 (11.25)	24 (9.96)	
<i>NR</i>	0 (0)	1 (0.41)	
Tumor size			
<i>All</i>	18.65 (8.70) [‡]	16.90 (7.94) [‡]	0.101
<i><18 cm</i>	40 (50.00)	135 (56.02)	0.095
<i>>18 cm</i>	39 (48.75)	92 (38.17)	
<i>NR</i>	1 (1.25)	14 (5.81)	

Multilocation			
<i>Yes</i>	52 (65.00)	153 (63.49)	0.081
<i>No</i>	28 (35.00)	74 (30.71)	
<i>NR</i>	0 (0)	14 (5.80)	
MDM2 score			
<i>0</i>	11 (13.75)	NA	NA
<i>1</i>	12 (15.00)	NA	
<i>2</i>	39 (48.75)	NA	
<i>3</i>	5 (6.25)	NA	
<i>4</i>	9 (11.25)	NA	
<i>NR</i>	4 (5.00)	NA	
LEP score	NA	1.62 (0.82) [†]	NA
LEP strength			
<i>0</i>	NA	10 (4.15)	NA
<i>1</i>	NA	39 (16.18)	
<i>2</i>	NA	74 (30.71)	
<i>3</i>	NA	115 (47.72)	
<i>NR</i>	NA	3 (1.24)	
PTTG1 score	NA	0.83 (0.75) [†]	NA
PTTG1 strength			
<i>0</i>	NA	38 (15.77)	NA
<i>1</i>	NA	100 (41.49)	
<i>2</i>	NA	61 (25.31)	
<i>3</i>	NA	39 (16.18)	
<i>NR</i>	NA	3 (1.25)	

215 [†]Clinical information missing in 8 RPLS patients (Training cohort 2)

216 [‡]*The data is shown as Mean (SD); other data is shown as Number (%)*

217 ^{††}*The definition of surgical times is the sum of current admission surgery and previous surgical resection*


218 *DDLs, Dedifferentiated liposarcoma; LEP, Leptin; MDM2, Mouse double minute 2; MLS, Myxoid*

219 *liposarcoma; NA, Not applicable; NR, Not reported; PLS, Pleomorphic liposarcoma; PTTG1, Pituitary tumor*

220 *transforming gene 1; WDLs, Well-differentiated liposarcoma*

221 ***Cell cycle, DNA damage and repair, and Metabolism are dysregulated in RPLS***

222 To reveal the general molecular features of RPLS compared to noncancerous adipose
223 tissues, we first recruited 8 RPLS patients and collected paired tumor and normal tissues for
224 differentially expressed gene (DEG) analysis. A total of 1354 DEGs, 554 upregulated and 800
225 downregulated, were identified (Figure 2A-B). To assess the underlying pathways of RPLS,
226 GSEA analyses were performed for those DEGs. We found that proliferation-associated
227 pathways, such as Mitotic spindle, E2F target, G2/M checkpoint and Separation of sister
228 chromatids, were mainly enriched in tumors; while metabolism-related pathways, such as Bile
229 acid metabolism, Heme and fatty acid metabolism and Integration of energy metabolism, were
230 enriched in normal controls (Figure 2C).




231
 232 **Figure 2. Cell cycle, DNA damage and repair, and metabolism are dysregulated in RPLS**
 233 **A.** Volcano plot of the DEGs in 8 normal vs 8 RPLS tissues. **B.** Venn diagram showed shared genes between
 234 DEGs and prognostic genes. **C.** GSEA analysis of RPLS tumors, including HALLMARK gene sets and
 235 REACTOME gene sets. **D.** Circular plots of the prognostic genes in GO, KEGG, and enrichWP.

236
 237 Then, we collected another 80 samples to investigate the molecular heterogeneity of RPLS.
 238 Gene expression profiles showed 918 and 3244 genes associated with overall survival (OS) and
 239 disease-free survival (DFS), respectively. Among 497 candidate genes associated with both OS
 240 and DFS, 83 of them also overlapped with DEGs (Figure 2B). Functional annotation (GO,
 241 KEGG, and enrichWP) demonstrated that Cell cycle, DNA damage and repair, and Metabolism-

242 related pathways were significantly enriched (Figure 2D), suggesting these signaling pathways
243 were dysregulated in RPLS.

244 *RPLS subgroups based on molecular features show different clinical outcomes*

245 To evaluate heterogeneous molecular clustering characteristics in RPLS, ssGSEA emerged
246 as a widely adopted method for computing the enrichment level of specific biological signaling
247 pathways for each sample based on gene expression data. This aids in gaining insights into the
248 overall activity level of signaling pathways. Here, we scored each sample on the dysregulated
249 pathways by ssGSEA and divided RPLS patients into two subgroups (Figure 3A). Subgroup 1
250 (G1) showed better OS and DFS compared to subgroup 2 (G2) (Figure 3B-C), G1 displayed
251 elevated ssGSEA scores associated with Metabolism, whereas G2 exhibited heightened ssGSEA
252 scores linked on Cell cycle and DNA damage and repair (Figure 3D). These features suggested
253 that effective monitoring of the prognosis of RPLS patients can be achieved based on the
254 activation status of specific pathways. We also evaluated the clinical features and immune
255 infiltration levels




256
 257 **Figure 3. RPLS subgroups (G1 and G2) based on cell cycle, DNA damage and repair, and metabolism**
 258 **A.** tSNE exhibited the subgroups (G1 and G2) of RPLS. **B-C.** Survival curves of OS (B) and DFS (C) in G1 and
 259 G2. **D.** The hierarchical clustering heatmap of dysregulated pathways in G1 and G2. **E-G.** Histograms
 260 revealed the difference of pathological composition ratio (E), surgery times (F), and MDM2 (G) in G1 and G2.
 261 **H.** Violin plot of the microenvironmental scores in G1 and G2.
 262 of those samples. The results showed that G1 had lower aggressive pathological composition
 263 ratio (Figure 3E), MDM2 (Figure 3G) and Ki67 (Figure S1A) expression, larger tumor size
 264 (Figure S1B), and higher tumor microenvironment (TME) level compared to G2 (Figure 3H).
 265 Surgery times for G1 were also tended to decrease (Figure 3F). Taken together, the above results

266 indicated that RPLS subgroups based on molecular features showed distinct clinical features and
267 clinical outcomes.

268 *A simplified RPLS classification strategy derived from RPLS G1/G2 subgroups*

269 To explore representative biomarkers for different RPLS subgroups, we performed a DEG
270 analysis between G1 and G2. There were 1258 genes downregulated, among which 112 of them
271 indicated good prognosis (protective genes). Correspondingly, 754 genes were upregulated, and
272 28 of them indicated poor prognosis (aggressive genes) (Figure S1C-D). Enrichment analysis
273 suggested that those DEGs were also associated with cell cycle regulation and metabolism
274 (Figure S1E), which was consistent with previous results (Figure 2C).

275 To develop a simplified RPLS clustering based on DEGs, we adopted NMF and tSNE for a
276 re-classification of those patients. The results showed RPLS patients were also divided into two
277 clusters (Figure 4A and Figure S1F-G). We then annotated the samples of two clusters by
278 ssGSEA and found Cluster1 (C1) was related to metabolic processes, and Cluster2 (C2) was
279 mainly related to the processes of Cell cycle and DNA damage and repair (Figure S2A). Also,
280 C1 showed better OS and DFS, lower pathological composition ratio and MDM2 expression, and
281 fewer surgery times (Figure 4B-F). Lower Ki67 expression and larger tumor size were observed
282 in C2 (Figure S2B-C). Interestingly, the biological annotations of the C1/C2 classification were
283 greatly consistent with G1/G2. Therefore, a simplified RPLS classification strategy derived from
284 RPLS subgroups was provisionally established.



285


286 **Figure 4. RPLS classification strategy (C1 and C2) derived from RPLS subgroups**

287 **A.** NMF for a re-classification of training cohort 1 (C1 and C2) (F). **B-C.** Survival curves of OS (B) and DFS
 288 (C) in C1 and C2. **D-F.** Histograms revealed the difference in pathological composition ratio (D), MDM2 (E),
 289 and surgery times (F) in C1 and C2.

290 **Development of a dichotomous RPLS classification model**

291 For NMF classification of RPLS patients, LEP and PTTG1 were identified as representative
 292 biomarkers of C1 and C2, respectively (Figure 5A). We aimed to replicate the RPLS
 293 classification of C1 and C2 by integrating these two biomarkers with the assistance of machine
 294 learning algorithms, and this two-gene panel achieved promising results (Logistic, AUC=0.995;
 295 SVM, AUC=0.997; RF, AUC=1.000; Figure 5B). Also, a linear negative correlation between
 296 LEP and PTTG1 expression was detected (Figure 5C). Considering the enhanced interpretability
 297 and generalization of linear models, we adopted the results of Logistic regression for subsequent
 298 analysis (Risk values= $2.182 \times \text{PTTG1} - 2.204 \times \text{LEP}$). The patients marked as high-risk (Cluster_H)
 299 exhibited worse OS and DFS than those marked as low-risk (Cluster_L) (Figure 5D-E).

300 Dysregulated pathways, such as DNA repair and Cell cycle regulation, were enriched in
 301 Cluster_H (Figure 5F and Figure S2D), and Cluster_H presented more aggressive pathological
 302 composition ratio, higher MDM2 levels and marginally increased in surgery times than
 303 Cluster_L (Figure 5G-I). Similarly, the Cluster_H showed higher Ki67 level and smaller tumor
 304 sizes (Figure S2E-F). Moreover, a Sankey diagram was drawn to show the correlation among
 305 G1/G2, C1/C2, and Cluster_L/H. Cluster_L/H were well-matched to C1/C2 and G1/G2,
 306 suggesting LEP and PTTG1 were promising biomarkers for a dichotomous RPLS classification
 307 (Figure 5J).



308
 309 **Figure 5. RPLS dichotomous classification (Cluster_C1 and Cluster_C2) derived from RPLS clusters**

310 *A. Heatmap of biomarkers identified (LEP and PTTG1) in C1 and C2. B. ROC curves of the machine learning*
311 *models to identify C1 and C2. C. Correlation between LEP and PTTG1 expression. D-E Survival curves of OS*
312 *(D) and DFS (E) in Cluster_C1 (low risk) and Cluster_C2 (high risk) groups. F. GSEA of HALLMARK gene*
313 *sets in Cluster_C1 and Cluster_C2. G-I. Histograms revealed the difference of pathological composition ratio*
314 *(G), MDM2 level (H), and surgery times (I) in Cluster_C1 and Cluster_C2. J. Sankey diagram indicated the*
315 *correlation among G1/G2, C1/C2, and Cluster_C1/C2.*

316 ***Validation of the dichotomous RPLS classification in another 241 RPLS patients***


317 To validate LEP and PTTG1 as biomarkers for a dichotomous RPLS classification, we
318 performed IHC staining of two biomarkers in validation cohort. The representative images of
319 LEP and PTTG1 with different expression levels were shown in Figure 6A-B. The IHC scores
320 were integrated with the previously fitted coefficients to evaluate the prognosis of RPLS patients
321 ($\text{Risk values} = 2.182 \times \text{PTTG1}_{\text{IHC}} - 2.204 \times \text{LEP}_{\text{IHC}}$). The cutoff value of validation cohort is the
322 median of risk value. The high-risk group had worse OS and DFS (Figure 6C-D), along with
323 more surgery times and more aggressive pathological composition ratio (Figure 7A-B), but the
324 difference of tumor size was not observed between the two groups (Figure 7C). Then we
325 constructed visual nomograms for a precise survival prediction of RPLS patients by combining
326 the risk score with clinical features. The predictive abilities of the 1-, 2-, and 3-year OS (Figure
327 7D-F) and DFS (Figure S3A-C) were 0.743-0.788. Together, we proposed a simple and
328 clinically applicable molecular classification strategy for RPLS patients.

329

330 **DISCUSSION**

331 Here we divided RPLS patients into two subgroups based on Cell cycle, DNA damage &
332 repair, and Metabolism-related pathways. G1 was annotated as Metabolism-active, which
333 exhibited high ssGSEA scores on Metabolism-associated pathways, while G2 showed high

334 ssGSEA scores on Cell cycle and DNA damage and repair with a high Ki67 and MDM2 level.
 335 G2



336
 337 **Figure 6. Validation of the RPLS dichotomous classification in another 241 RPLS cohort**
 338 **A-B.** Representative IHC staining images of LEP (A) and PTTG1 (B). **C-D.** Survival curves of OS (C) and DFS
 339 (D) in high-risk and low-risk groups.

340 had more aggressive molecular features and worse clinical outcomes compared to G1, in
341 accordance with previously reported tumor classification (*Lindskrog et al., 2021; Yu et al., 2021;*
342 *Zhang et al., 2022*). In fact, *Demicco et al., 2017* has integrated SCNA and DNA methylation
343 divide dedifferentiated liposarcoma into two subtypes (S1 and S2), the unfavorable cluster was
344 characterized as JUN amplified (An oncogene that promotes proliferation and metastasis) and
345 lower inferred fraction of immature dendritic cells. However, the patients in *Demicco et al., 2017*
346 were of complex origin (mixed limbs, trunk and retroperitoneum), providing limited guidance for
347 RPLS molecular classification. Here we reported the first clinically applicable RPLS molecular
348 classification based on RNA sequencing and IHC validation cohorts.

349 To facilitate the clinical application, we constructed a simplified RPLS molecular
350 classification derived from the original Cell cycle/Metabolism subgroups. By NMF algorithm,
351 we identified LEP and PTTG1 as representative biomarkers for each subtype. A model based on
352 IHC staining of LEP and PTTG1 successfully approximated the original dichotomous RPLS
353 classification in biological features and survival outcomes. LEP is an important regulator of basal
354 metabolism and food intake, which is considered a linkage between metabolism and the immune
355 system (*Jiménez-Cortegana et al., 2021*). Although LEP-based targeting therapies have not yet
356 been fully applied, LEP has already been identified as a potent metabolic reprogramming agent
357 to support antitumor responses in aggressive melanomas (*Waldman et al., 2020; De la et al.,*
358 *2019; Rivadeneira et al., 2019*). In addition, LEP improves the immunotherapeutic effects by
359 regulating innate and adaptive immune responses via increasing the cytotoxicity of NK cells
360 (*Vera et al., 2018*), stimulating the proliferation of T/B cells (*Vera et al., 2018; Bernotiene et al.,*
361 *2006*), and activating DC cells (*Hu et al., 2019*). Those reported roles of LEP provided a good
362 mechanism explanation on the features of metabolism pathway-enriched, better prognosis, higher


363 TME level of Metabolism subgroup (LEP+). In contrast, PTTG1 acts as a regulator of sister
364 chromatid separation during cell division under physiological conditions (Zou et al., 1999),
365 which is closely linked to genetic instability, aneuploidy, tumor progression, invasion, and
366 metastasis (*Heaney et al., 2000; Ramaswamy et al., 2003; Kim et al., 2005; Yu et al., 2003;*
367 *Teveroni et al., 2021; Romero et al., 2001*). PTTG1 also regulates the cell cycle and the
368 transactivation of growth factors as an initiator and promoter of tumorigenesis (*Zou et al., 1999;*
369 *Mora-Santos et al., 2013; McCabe et al., 2002; Ishikawa et al 2001; Hamid et al., 2005*).
370 Overexpressing PTTG1 was correlated with worse prognosis in tumors, such as ovarian cancer
371 (*Parte et al., 2019*), cervical cancer (*Guo et al., 2019*), renal cell carcinoma (*Tian et al., 2022*),
372 and colorectal cancer (*Heaney et al., 2000*). Therefore, the biological functions of PTTG1
373 provided a good mechanism explanation of the pathway-enriched of cell cycle/DNA damage &
374 repair-associated, worse prognosis, and more aggressive pathological composition ratio the Cell
375 cycle subgroup (PTTG1+).

376

377 **CONCLUSION**

378 Our study presented a comprehensive gene expression landscape of RPLS, revealing distinct
379 molecular features. Through categorizing RPLS into Metabolism and Cell Cycle subtypes and
380 identifying key biomarkers LEP and PTTG1, we established a dichotomous classification system
381 verified by IHC assays. This innovative approach enables precise guidance for surgeons in
382 adjusting treatment strategies for patients with histologically favorable but prognostically
383 challenging RPLS cases, thereby advancing the implementation of precision medicine in guiding
384 surgical interventions for RPLS.

385



386 **Figure 7. Survival nomogram of LEP+PTTG1 model in validation cohort**

387 **A-C.** The difference of surgery times (A), pathological composition (B), and surgery times (C) in high-risk and
 388 low-risk groups. **D.** Nomograms for OS was developed in REASR cohort with four factors: sex, age, risk score,
 389 and differentiation. **E.** ROC curves of 1-, 2-, and 3-year OS in validation cohort. **F.** Calibration curves of
 390 predicting 1-, 2-, and 3-year OS in validation cohort.

391

392 **Abbreviations**

393	RPLS	Retroperitoneal liposarcoma
394	DEGs	Differentially expressed genes
395	IHC	Immunohistochemistry
396	STS	Soft tissue sarcoma
397	OS	Overall survival
398	DFS	Disease-free survival
399	OMIX	Open archive for miscellaneous data
400	CNCB	China national center for bioinformation
401	GSEA	Gene set enrichment analysis
402	GO	Gene ontology
403	KEGG	Kyoto encyclopedia of gene and genomes
404	t-SNE	t-distributed stochastic neighbor embedding
405	DBSCAN	Density-based spatial clustering of applications with noise
406	NMF	Nonnegative matrix factorization
407	LR	Logistic regression
408	SVM	Support vector machine
409	RF	Random forest
410	AUC	Area under curve

411

412

413 **Authors' contributors**

414 Mengmeng Xiao: Methodology, Formal analysis, Data curation, Writing-original draft, Writing-
415 review & editing. Xiang Ji Li: Methodology, Formal analysis, Investigation, Data curation,
416 Writing-original draft. Fanqin Bu: Conceptualization, Methodology, Formal analysis,
417 Investigation, Data curation, Writing-review & editing. Shixiang Ma: Methodology, Formal
418 analysis. Xiaohan Yang: Methodology, Investigation. Jun Chen: Formal analysis. Yu Zhao:
419 Investigation. Ferdinando Cananzi: Investigation. Chenghua Luo: Conceptualization,
420 Methodology, Writing-review & editing, Supervision. Li Min: Conceptualization, Resources,
421 Writing-review & editing, Supervision.

422

423 **Ethics approval and consent to participate**

424 Specimens of RPLS were obtained from Peking University International Hospital. The study
425 protocol was approved by the Ethics Committee of Peking University International Hospital,
426 Peking University Health Science Center (WA2020RW29) and conducted in accordance with
427 Helsinki Declaration. All patients signed the informed consent.

428

429 **Finding information**

430 This work was supported by grants from the Beijing Municipal Science and Technology Project
431 (Z191100006619081), National Natural Science Foundation of China (82073390), and Young
432 Elite Scientists Sponsorship Program (2023QNRC001). The study sponsors had no role in the
433 design and preparation of this manuscript.

434

435 **Research registration unique identifying number (UIN)**

- 436 1. Name of the registry: ClinicalTrials.gov
437 2. Unique identifying number or registration ID: NCT03838718
438 3. Hyperlink to your specific registration: <https://clinicaltrials.gov>

439

440 **Consent for publication**

441 All authors have read and approved the manuscript and agree with submission to *eLife*.

442

443 **Data availability**

444 Data supporting the conclusions of this article are presented within the article and its
445 supplementary files.

446

447 **Competing interests**

448 The authors declare that they have no competing interests.

449

450 **REFERENCES**

- 451 **Ecker BL**, Peters MG, McMillan MT, Sinnamon AJ, Zhang PJ, Fraker DL, Levin WP, Roses
452 RE, Karakousis GC. Preoperative radiotherapy in the management of retroperitoneal liposarcoma.
453 *Br J Surg*. 2016; 103(13): 1839-1846. doi: 10.1002/bjs.10305
- 454 **Littau MJ**, Kulshrestha S, Bunn C, Agnew S, Sweigert P, Luchette FA, Baker MS. The
455 importance of the margin of resection and radiotherapy in retroperitoneal liposarcoma. *Am J*
456 *Surg*. 2021;221(3):554-560. doi:10.1016/j.amjsurg.2020.11.041
- 457 **Gronchi A**, Miceli R, Allard MA, Callegaro D, Le Péchoux C, Fiore M, Honoré C, Sanfilippo R,
458 Coppola S, Stacchiotti S, Terrier P, Casali PG, Cesne AL, Mariani L, Colombo C, Bonvalot S.
459 Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of
460 failure and postrelapse outcome after primary extended resection. *Ann Surg Oncol*.
461 2015;22(5):1447-1454. doi:10.1245/s10434-014-4130-7
- 462 **Gronchi A**, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E,
463 Mariani L, Casali PG. Aggressive surgical policies in a retrospectively reviewed single-
464 institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol*.
465 2009;27(1):24-30. doi:10.1200/JCO.2008.17.8871
- 466 **Gronchi A**, Pollock RE. Quality of local treatment or biology of the tumor: which are the trump
467 cards for loco-regional control of retroperitoneal sarcoma?. *Ann Surg Oncol*. 2013;20(7):2111-
468 2113. doi:10.1245/s10434-013-2971-0
- 469 **Pisters PW**. Resection of some -- but not all -- clinically uninvolved adjacent viscera as part of
470 surgery for retroperitoneal soft tissue sarcomas. *J Clin Oncol*. 2009;27(1):6-8.
471 doi:10.1200/JCO.2008.18.7138

- 472 **Kam AE**, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract
473 cancers. *Lancet Gastroenterol Hepatol.* 2021;6(11):956-969. doi:10.1016/S2468-
474 1253(21)00171-0
- 475 **Zeng Y**, Jin RU. Molecular pathogenesis, targeted therapies, and future perspectives for gastric
476 cancer. *Semin Cancer Biol.* 2022;86(Pt 3):566-582. doi:10.1016/j.semcancer.2021.12.004
- 477 **Alifrangis C**, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology
478 directed therapy for advanced bladder cancer. *Nat Rev Urol.* 2019;16(8):465-483.
479 doi:10.1038/s41585-019-0208-0
- 480 **Frese KK**, Simpson KL, Dive C. Small cell lung cancer enters the era of precision medicine.
481 *Cancer Cell.* 2021;39(3):297-299. doi:10.1016/j.ccell.2021.02.002
- 482 **Pilotti S**, Della Torre G, Mezzelani A, Tamborini E, Azzarelli A, Sozzi G, Pierotti MA. The
483 expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated
484 liposarcoma and large deep-seated lipoma. *Br J Cancer.* 2000;82(7):1271-1275.
485 doi:10.1054/bjoc.1999.1090
- 486 **Binh MB**, Sastre-Garau X, Guillou L, Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I,
487 Coindre JM. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-
488 differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft
489 tissue neoplasms with genetic data. *Am J Surg Pathol.* 2005;29(10):1340-1347.
490 doi:10.1097/01.pas.0000170343.09562.39
- 491 **Yen CC**, Chen SC, Hung GY, Wu PK, Chua WY, Lin YC, Yen CH, Chen YC, Wang JY, Yang
492 MH, Chao Y, Chang MC, Chen WM. Expression profile-driven discovery of AURKA as a
493 treatment target for liposarcoma. *Int J Oncol.* 2019;55(4):938-948. doi:10.3892/ijo.2019.4861

- 494 **Yang L**, Wu Z, Sun W, Luo P, Chen S, Chen Y, Yan W, Li Y, Wang C. CCNDBP1, a
495 Prognostic Marker Regulated by DNA Methylation, Inhibits Aggressive Behavior in
496 Dedifferentiated Liposarcoma via Repressing Epithelial Mesenchymal Transition. *Front Oncol.*
497 2021;11:687012. doi:10.3389/fonc.2021.687012
- 498 **McShane LM**, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting
499 recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer.*
500 2005;93(4):387-391.
- 501 **Guo L**, Chen G, Zhang W, Zhou L, Xiao T, Di X, Wang Y, Feng L, Zhang K. A high-risk
502 luminal A dominant breast cancer subtype with increased mobility. *Breast Cancer Res Treat.*
503 2019;175(2):459-472. doi:10.1007/s10549-019-05135-w
- 504 **Li X**, Bu F, Ma S, Cananzi F, Zhao Y, Xiao M, Min L, Luo C. The Janus-faced role of TRPM2-
505 S in retroperitoneal liposarcoma via increasing ROS levels. *Cell Commun Signal.*
506 2022;20(1):128. doi:10.1186/s12964-022-00873-9
- 507 **Lindskrog SV**, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB,
508 Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG,
509 Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjødahl G, Höglund M, Steiniche T,
510 Mogensen K, Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst
511 C, Kessel K, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A,
512 Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L. An integrated multi-omics
513 analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. *Nat*
514 *Commun.* 2021;12(1):2301.
- 515 **Yu Z**, Deng P, Chen Y, Liu S, Chen J, Yang Z, Chen J, Fan X, Wang P, Cai Z, Wang Y, Hu P,
516 Lin D, Xiao R, Zou Y, Huang Y, Yu Q, Lan P, Tan J, Wu X. Inhibition of the PLK1-Coupled

517 Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer. *Adv Sci*
518 (*Weinh*). 2021;8(23):e2100759.

519 **Zhang F**, Zhang Q, Zhu J, Yao B, Ma C, Qiao N, He S, Ye Z, Wang Y, Han R, Feng J, Wang Y,
520 Qin Z, Ma Z, Li K, Zhang Y, Tian S, Chen Z, Tan S, Wu Y, Ran P, Wang Y, Ding C, Zhao Y.
521 Integrated proteogenomic characterization across major histological types of pituitary
522 neuroendocrine tumors. *Cell Res*. 2022;32(12):1047-1067.

523 **Cancer Genome Atlas Research Network**. Electronic address:
524 elizabeth.demicco@sinaihealthsystem.ca; Cancer Genome Atlas Research Network.
525 Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell*.
526 2017;171(4):950-965.e28. doi:10.1016/j.cell.2017.10.014

527 **Jiménez-Cortegana C**, López-Saavedra A, Sánchez-Jiménez F, Pérez-Pérez A, Castiñeiras J,
528 Virizuela-Echaburu JA, Cruz-Merino L, Sánchez-Margalet V. Leptin, Both Bad and Good Actor
529 in Cancer. *Biomolecules*. 2021;11(6):913. doi:10.3390/biom11060913

530 **Waldman AD**, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic
531 science to clinical practice. *Nat Rev Immunol*. 2020;20(11):651-668. doi:10.1038/s41577-020-
532 0306-5

533 **De la Cruz-Merino L**, Palazón-Carrión N, Henao-Carrasco F, Nogales-Fernández E, Álamo-de
534 la Gala A, Vallejo-Benítez A, Chiesa M, Sánchez-Margalet V. New horizons in breast cancer:
535 the promise of immunotherapy. *Clin Transl Oncol*. 2019;21(2):117-125. doi:10.1007/s12094-
536 018-1907-3

537 **Rivadeneira DB**, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, Sampath P, Lafyatis R,
538 Ferris RL, Sarkar SN, Thorne SH, Delgoffe GM. Oncolytic Viruses Engineered to Enforce

539 Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor
540 Clearance. *Immunity*. 2019;51(3):548-560.e4. doi:10.1016/j.immuni.2019.07.003

541 **Vera F**, Pino J, Campos-Cabaleiro V, Ruiz-Fernández C, Mera A, Gonzalez-Gay MA, Gómez R,
542 Gualillo O. Obesity, Fat Mass and Immune System: Role for Leptin. *Front Physiol*. 2018;9:640.
543 doi: 10.3389/fphys.2018.00640

544 **Bernotiene E**, Palmer G, Gabay C. The role of leptin in innate and adaptive immune responses.
545 *Arthritis Res Ther*. 2006;8(5):217. doi:10.1186/ar2004

546 **Hu W**, Wang G, Huang D, Sui M, Xu Y. Cancer Immunotherapy Based on Natural Killer Cells:
547 Current Progress and New Opportunities. *Front Immunol*. 2019;10:1205.
548 doi:10.3389/fimmu.2019.01205

549 **Zou H**, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid
550 separation inhibitor involved in transformation and tumorigenesis. *Science*. 1999;285(5426):418-
551 422. doi:10.1126/science.285.5426.418

552 **Heaney AP**, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of
553 pituitary-tumour transforming gene in colorectal tumours. *Lancet*. 2000;355(9205):716-719.
554 doi:10.1016/S0140-6736(99)10238-1

555 **Ramaswamy S**, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary
556 solid tumors. *Nat Genet*. 2003;33(1):49-54. doi:10.1038/ng1060

557 **Kim D**, Pemberton H, Stratford AL, Buelaert K, Watkinson JC, Lopes V, Franklyn JA, McCabe
558 CJ. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells.
559 *Oncogene*. 2005;24(30):4861-4866. doi:10.1038/sj.onc.1208659

- 560 **Yu R**, Lu W, Chen J, McCabe CJ, Melmed S. Overexpressed pituitary tumor-transforming gene
561 causes aneuploidy in live human cells. *Endocrinology*. 2003;144(11):4991-4998.
562 doi:10.1210/en.2003-0305
- 563 **Teveroni E**, Di Nicuolo F, Bianchetti G, Epstein AL, Grande G, Maulucci G, Spirito MD,
564 Pontecorvi A, Milardi D, Mancini F. Nuclear Localization of PTTG1 Promotes Migration and
565 Invasion of Seminoma Tumor through Activation of MMP-2. *Cancers (Basel)*. 2021;13(2):212.
566 doi:10.3390/cancers13020212
- 567 **Romero F**, Multon MC, Ramos-Morales F, Domínguez A, Bernal JA, Pintor-Toro JA, Tortolero
568 M. Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the
569 DNA-dependent protein kinase. *Nucleic Acids Res*. 2001;29(6):1300-1307.
570 doi:10.1093/nar/29.6.1300
- 571 **Mora-Santos M**, Castilla C, Herrero-Ruiz J, Giráldez S, Limón-Mortés MC, Sáez C, Japón MÁ,
572 Tortolero M, Romero F. A single mutation in Securin induces chromosomal instability and
573 enhances cell invasion. *Eur J Cancer*. 2013;49(2):500-510. doi:10.1016/j.ejca.2012.06.024
- 574 **McCabe CJ**, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S,
575 Sheppard MC, Franklyn JA, Gittoes NJL. Vascular endothelial growth factor, its receptor
576 KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. *J Clin Endocrinol Metab*.
577 2002;87(9):4238-4244. doi:10.1210/jc.2002-020309
- 578 **Ishikawa H**, Heaney AP, Yu R, Horwitz GA, Melmed S. Human pituitary tumor-transforming
579 gene induces angiogenesis. *J Clin Endocrinol Metab*. 2001;86(2):867-874.
580 doi:10.1210/jcem.86.2.7184

581 **Hamid T**, Malik MT, Kakar SS. Ectopic expression of PTTG1/securin promotes tumorigenesis
582 in human embryonic kidney cells. *Mol Cancer*. 2005;4(1):3. Published 2005 Jan 13.
583 doi:10.1186/1476-4598-4-3

584 **Parte S**, Virant-Klun I, Patankar M, Batra SK, Straughn A, Kakar SS. PTTG1: a Unique
585 Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer. *Stem Cell Rev Rep*.
586 2019;15(6):866-879. doi:10.1007/s12015-019-09911-5

587 **Guo XC**, Li L, Gao ZH, Zhou HW, Li J, Wang QQ. The long non-coding RNA PTTG3P
588 promotes growth and metastasis of cervical cancer through PTTG1. *Aging (Albany NY)*.
589 2019;11(5):1333-1341. doi:10.18632/aging.101830

590 **Tian X**, Xu WH, Xu FJ, Li H, Anwaier A, Wang HK, Wan FN, Zhu Y, Cao DL, Zhu YP, Shi
591 GH, Qu YY, Zhang HL, Ye DW. Identification of prognostic biomarkers in papillary renal cell
592 carcinoma and PTTG1 may serve as a biomarker for predicting immunotherapy response. *Ann*
593 *Med*. 2022;54(1):211-226.

594

595 **Table 1. Baseline characteristics of training cohort and validation cohort**

596

597 **Figure Legend**

598 **Figure 1. Flow diagram of exploring RPLS dichotomous classification**

599

600 **Figure 2. Cell cycle, DNA damage and repair, and metabolism are dysregulated in RPLS**

601 Volcano plot of the DEGs in 8 normal vs 8 RPLS tissues (A). Venn diagram showed shared
602 genes between DEGs and prognostic genes (B). GSEA analysis of RPLS tumors, including
603 HALLMARK gene sets and REACTOME gene sets (C). Circular plots of the prognostic genes
604 in GO, KEGG, and enrichWP (D).

605

606 **Figure 3. RPLS subgroups (G1 and G2) based on cell cycle, DNA damage and repair, and**
607 **metabolism**

608 tSNE exhibited the subgroups (G1 and G2) of RPLS (A). Survival curves of OS (B) and DFS (C)
609 in G1 and G2. The hierarchical clustering heatmap of dysregulated pathways in G1 and G2 (D).
610 Histograms revealed the difference of pathological composition ratio (E), surgery times (F), and
611 MDM2 (G) in G1 and G2. Violin plot of the microenvironmental scores in G1 and G2 (H).

612

613 **Figure 4. RPLS classification strategy (C1 and C2) derived from RPLS subgroups**

614 NMF for a re-classification of training cohort 1 (C1 and C2) (A). Survival curves of OS (B) and
615 DFS (C) in C1 and C2. Histograms revealed the difference in pathological composition ratio (D),
616 MDM2 (E), and surgery times (F) in C1 and C2.

617

618 **Figure 5. RPLS dichotomous classification (Cluster_C1 and Cluster_C2) derived from**
619 **RPLS clusters**

620 Heatmap of biomarkers identified (LEP and PTTG1) in C1 and C2 (A). ROC curves of the
621 machine learning models to identify C1 and C2 (B). Correlation between LEP and PTTG1
622 expression (C). Survival curves of OS (D) and DFS (E) in Cluster_C1 (low risk) and Cluster_C2
623 (high risk) groups. GSEA of HALLMARK gene sets in Cluster_C1 and Cluster_C2 (F).
624 Histograms revealed the difference of pathological composition ratio (G), MDM2 level (H), and
625 surgery times (I) in Cluster_C1 and Cluster_C2. Sankey diagram indicated the correlation among
626 G1/G2, C1/C2, and Cluster_C1/C2 (J).

627

628 **Figure 6. Validation of the RPLS dichotomous classification in another 241 RPLS cohort**

629 Representative IHC staining images of LEP (A) and PTTG1 (B). Survival curves of OS (C) and
630 DFS (D) in high-risk and low-risk groups.

631

632 **Figure 7. Survival nomogram of LEP+PTTG1 model in validation cohort**

633 The difference of surgery times (A), pathological composition (B), and surgery times (C) in
634 high-risk and low-risk groups. Nomograms for OS was developed in REASR cohort with four
635 factors: sex, age, risk score, and differentiation (D). ROC curves of 1-, 2-, and 3-year OS in
636 validation cohort (E). Calibration curves of predicting 1-, 2-, and 3-year OS in validation cohort
637 (F).

638

639 **Supplementary Information**

640 **Table S1.** The detailed clinicopathological characteristics of the training cohort 1

641 **Table S2.** The RNA-seq data of the training cohort 2

642 **Table S3.** The detailed clinicopathological characteristics of the validation cohort

643 **Table S4.** The RNA-seq data of the training cohort 1

644

645 **Figure S1. Clinical features and re-classification of RPLS subgroups (G1 and G2)**

646 The difference of Ki67 (A) and tumor size (B) in G1 and G2. Volcano plot of the DEGs (G1 vs

647 G2) (C). Venn diagram showed shared genes between DEGs and prognostic genes (D). Bubble

648 plot of the DEGs enrichment (E). NMF for a re-classification of training cohort 1 (F). tSNE

649 exhibits the RPLS clusters (C1 and C2) (G).

650

651 **Figure S2. Dysregulated pathways and clinical features of RPLS clusters and high-/low-**
652 **risk groups**

653 The hierarchical clustering heatmap of dysregulated pathways in C1 and C2 (A). The difference

654 of Ki67 (B) and tumor size (C) in C1 and C2. The hierarchical clustering heatmap of

655 dysregulated pathways in high- and low-risk groups (D). The difference of tumor size (E) and

656 Ki67 (F) in high- and low-risk groups.


657

658 **Figure S3. Survival nomogram of LEP+PTTG1 model in validation cohort**


659 Nomograms for DFS was developed in REASR cohort with four factors: sex, age, risk score, and

660 differentiation (A). ROC curves of 1-, 2-, and 3-year DFS in validation cohort (B). Calibration


661 curves of predicting 1-, 2-, and 3-year DFS (C).




A




B

















C







D

















A**B****C****D**

Cluster_C1	32	31	29	28	23	13	1
Cluster_C2	42	40	32	21	10	3	0
	0	6	12	18	24	30	36
	Time in months						

E

Cluster_C1	32	30	25	18	12	6
Cluster_C2	44	25	12	6	3	1
	0	6	12	18	24	30
	Time in months					

F**G****H****I****J**

A**LEP (leptin)****B****PTTG1 (securin)****C****D**







A**B****C****D****E****F**

Table 1 Baseline characteristics of training cohort and validation cohort

	Training cohort (N=80) [†]	Validation cohort (N=241)	P value
Age (y)	56.34 (11.14) [‡]	55.11 (10.80) [‡]	0.384
Sex			
<i>Male</i>	37 (46.25)	118 (48.96)	0.674
<i>Female</i>	43 (53.75)	123 (51.04)	
Pathology			
<i>WDLS</i>	29 (36.25)	75 (31.12)	0.078
<i>DDLS</i>	48 (60.00)	144 (59.75)	
<i>MLS and PLS</i>	3 (3.75)	5 (2.07)	
<i>NR</i>	0 (0)	17 (7.06)	
Surgery times^{††}			
<i>0-1</i>	50 (62.50)	143 (59.34)	0.834
<i>2-3</i>	21 (26.25)	73 (30.29)	
<i>4-7</i>	9 (11.25)	24 (9.96)	
<i>NR</i>	0 (0)	1 (0.41)	
Tumor size			
<i>All</i>	18.65 (8.70) [‡]	16.90 (7.94) [‡]	0.101
<i><18 cm</i>	40 (50.00)	135 (56.02)	0.095
<i>>18 cm</i>	39 (48.75)	92 (38.17)	
<i>NR</i>	1 (1.25)	14 (5.81)	
Multilocation			
<i>Yes</i>	52 (65.00)	153 (63.49)	0.081
<i>No</i>	28 (35.00)	74 (30.71)	
<i>NR</i>	0 (0)	14 (5.80)	
MDM2 score			
<i>0</i>	11 (13.75)	NA	NA
<i>1</i>	12 (15.00)	NA	
<i>2</i>	39 (48.75)	NA	
<i>3</i>	5 (6.25)	NA	
<i>4</i>	9 (11.25)	NA	
<i>NR</i>	4 (5.00)	NA	
LEP score	NA	1.62 (0.82) [‡]	NA
LEP strength			
<i>0</i>	NA	10 (4.15)	NA
<i>1</i>	NA	39 (16.18)	
<i>2</i>	NA	74 (30.71)	
<i>3</i>	NA	115 (47.72)	
<i>NR</i>	NA	3 (1.24)	
PTTG1 score	NA	0.83 (0.75) [‡]	NA
PTTG1 strength			
<i>0</i>	NA	38 (15.77)	NA

<i>1</i>	NA	100 (41.49)	
<i>2</i>	NA	61 (25.31)	
<i>3</i>	NA	39 (16.18)	
<i>NR</i>	NA	3 (1.25)	

[†]Clinical information missing in 8 RPLS patients (Training cohort 2)

[‡]The data is shown as Mean (SD); other data is shown as Number (%)

^{††}The definition of surgical times is the sum of current admission surgery and previous surgical resection

DDLS, Dedifferentiated liposarcoma; LEP, Leptin; MDM2, Mouse double minute 2; MLS, Myxoid liposarcoma; NA, Not applicable; NR, Not reported; PLS, Pleomorphic liposarcoma; PTTG1, Pituitary tumor transforming gene 1; WDLS, Well-differentiated liposarcoma